© Reuters. South Korean court suspends regulator’s disciplinary action against Samsung BioLogics

SEOUL (Reuters) – A South Korean court has suspended the financial regulator’s disciplinary action against Samsung (KS:) BioLogics Co Ltd (KS:) over breach of accounting rules, an official at the Seoul Administrative Court said on Tuesday.

Samsung BioLogics filed an administrative lawsuit to overturn the watchdog’s ruling on accounting violations and sought a court injunction to restrain the disciplinary action until the court reaches a conclusion.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link